Effects of GLP ‐1 agonists on the gut microbiota in type 2 diabetes mellitus: a systematic review
Wirkungen von GLP-1-Agonisten auf die Darmmikrobiota bei Typ-2-Diabetes mellitus: systematische Übersichtsarbeit
The FEBS Journal · 2026-10 · 293 (20) · 5971-5995
DOI: 10.1111/febs.70656 ↗Auf einen Blick
Die Übersichtsarbeit fand, dass GLP-1-Agonisten die Darmmikrobiota bei T2DM verändern. Beschrieben wurden unter anderem mehr Bacteroidetes, Akkermansia muciniphila und Lactobacillus.
Fragestellung
Welche Effekte haben GLP-1-Agonisten auf die Darmmikrobiota bei Menschen mit Typ-2-Diabetes mellitus?
Methode
Systematische Übersichtsarbeit; Suche in PubMed, Scopus, Web of Science und Embase im März 2025; 2 Reviewer werteten Titel und Abstracts aus.
Ergebnisse
17 Studien wurden eingeschlossen: 12 präklinische und 5 klinische. GLP-1-Agonisten waren mit Veränderungen der Mikrobiota, besserer Darmstruktur, mehr Occludin-Expression und weniger Kolonentzündung verbunden.
Einschränkungen
Weitere klinische Studien sind erforderlich, um die Befunde zu bestätigen.
Schlussfolgerung der Autor:innen
GLP-1-Agonisten beeinflussen die intestinale Mikrobiota und verbessern metabolische Parameter sowie antiinflammatorische Effekte.
Kernaussagen
- 17 eingeschlossene Studien: 12 präklinische, 5 klinische
- Veränderungen der Mikrobiota mit mehr eubiotischen Bakterien
- Weitere klinische Studien zur Bestätigung erforderlich
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
At a glance
Systematische Übersicht in The FEBS Journal, published online on 2026-08-20. Written by Ranicleide Santos Dantas and 11 co-authors. Institution: Department of Pharmacy, Federal University of Sergipe, Brazil. Major MEDLINE topics: Diabetes Mellitus, Type 2, Gastrointestinal Microbiome, Glucagon-Like Peptide 1, Glucagon-Like Peptide-1 Receptor Agonists. Cited 1 times so far (Crossref); 93 references. The full text is freely available (open access, CC BY 4.0).
Topics: Diabetes mellitus
Abstract (original language)
Diabetes mellitus (DM) is a metabolic disease characterised by chronic hyperglycemia. The Glucagon‐Like Peptide‐1 Receptor Agonists (GLP‐1 RAs) used in type 2 diabetes mellitus (T2DM) have been highlighted for their potential benefits to the gut microbiota in the context of this pathology. Therefore, it is important to investigate the relationship between microbiota and GLP‐1 RAs used in T2DM. This review aimed at evaluating the effects of GLP‐1 agonists on gut microbiota in T2DM individuals. The protocol was previously registered in PROSPERO, and the search was conducted in PubMed, Scopus, Web of Science, and Embase databases in March 2025. Two reviewers have read the titles and abstracts and selected the included articles based on established criteria. The initial search identified 5532 publications, of which 17 studies were included: 12 preclinical and 5 clinical. Most were conducted in China between 2016 and 2025. GLP‐1 agonists have been shown to modulate the gut microbiota, characterised by an increase in Bacteroidetes, Akkermansia muciniphila , and Lactobacillus . These changes are accompanied by an improvement of intestinal villi, increase in occludin expression, as well as an improvement in colonic inflammation. We identified a higher abundance of bacterial species associated with intestinal balance (eubiosis), accompanied by reduced inflammation and insulin resistance. Conversely, there was a lower abundance of bacteria related to dysbiosis, such as Firmicutes and Proteobacteria , which can be unfavourable when in excess. GLP‐1 agonists influence the intestinal microbiota, improving metabolic parameters and anti‐inflammatory effects. However, further clinical studies are needed to corroborate the findings of this review.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pharmacy, Federal University of Sergipe, Brazil.
- Postgraduate Program in Pharmaceutical Sciences, Federal University of Sergipe, Brazil.
- Northeast Biotechnology Network (RENORBIO), Federal University of Sergipe, Brazil.
- Postgraduate Pharmacy Program (Pathophysiology and Toxicology), University of São Paulo, Brazil.
- School of Dentistry, Federal University of Sergipe, Brazil.
- Division of Phytochemistry and Drug Design, Department of Biosciences, Rajagiri College of Social Sciences, Kochi, Kerala, India.
ORCID profiles: Ranicleide Santos Dantas, Marina Dos Santos Barreto, Lysandro Pinto Borges
Cite
APA
Santos Dantas, R., Souza Santos, L. V., Carvalho de Oliveira, A. G., Dos Santos Barreto, M., Rego Rodrigues Silva, D. M., Macedo Moura, P. H., Dias Silva, E. E., Santana Santos, R., Alves da Mota Santana, L., Gandhi Gopalsamy, R., Gibara Guimarães, A., & Pinto Borges, L. (2026). Effects of GLP ‐1 agonists on the gut microbiota in type 2 diabetes mellitus: a systematic review. The FEBS Journal, 293(20), 5971-5995. https://doi.org/10.1111/febs.70656
Vancouver
Santos Dantas R, Souza Santos LV, Carvalho de Oliveira AG, Dos Santos Barreto M, Rego Rodrigues Silva DM, Macedo Moura PH, et al. Effects of GLP ‐1 agonists on the gut microbiota in type 2 diabetes mellitus: a systematic review. The FEBS Journal. 2026;293(20):5971-5995. doi:10.1111/febs.70656
BibTeX
@article{SantosDantas2026,
author = {Santos Dantas, Ranicleide and Souza Santos, Lucas Vinícius and Carvalho de Oliveira, André Gustavo and Dos Santos Barreto, Marina and Rego Rodrigues Silva, Deise Maria and Macedo Moura, Pedro Henrique and Dias Silva, Eloia Emanuelly and Santana Santos, Ronaldy and Alves da Mota Santana, Lucas and Gandhi Gopalsamy, Rajiv and Gibara Guimarães, Adriana and Pinto Borges, Lysandro},
title = {Effects of GLP ‐1 agonists on the gut microbiota in type 2 diabetes mellitus: a systematic review},
journal = {The FEBS Journal},
year = {2026},
volume = {293},
number = {20},
pages = {5971--5995},
doi = {10.1111/febs.70656}
}
EUVIMED